This poster describes development of an immediate-release (IR) product for a crystalline drug using a lipid multiparticulate (LMP) formulation platform. The goal was to demonstrate a platform that can be used to develop a formulation suitable for first-in-human (safety) and proof-of-concept (efficacy) clinical trials. This project demonstrated material-sparing techniques, using less than 50 gm of active pharmaceutical ingredient, on a timeline of less than 3 months, demonstrating the flexibility and utility of this approach. To learn more, please see our poster.
Content Type: Poster
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center